Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Allergy Clin Immunol ; 153(6): 1681-1691.e12, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38142822

RESUMEN

BACKGROUND: The upper respiratory tract is continuously exposed to microorganisms and noxious elements, leading to local immune responses and the secretion of immune markers. While several studies describe immune marker profiles in respiratory mucosal samples in defined patient cohorts, mucosal immune profiles from the general population during the different seasons are lacking. Such baseline profiles are essential to understand the effect of various exposures to the mucosal immune system throughout life. OBJECTIVE: We sought to establish baseline local upper respiratory mucosal immune profiles in the general population and assess these profiles with regard to age, sex, seasonality, and basic health and lifestyle factors. METHODS: We measured the concentrations of 35 immune markers involved in a broad range of immunological processes at the mucosa in nasopharyngeal swab samples from 951 individuals, aged 0 to 86 years, from a nationwide study. RESULTS: Clustering analysis showed that immune marker profiles clearly reflected immunological functions, such as tissue regeneration and antiviral responses. Immune marker concentrations changed strongly with seasonality and age, with the most profound changes occurring in the first 25 years of life; they were also associated with sex, body mass index, smoking, mild symptoms of airway infection, and chronic asthma and hay fever. CONCLUSION: Immunological analyses of noninvasive mucosal samples provide insight into mucosal immune responses to microbial and noxious element exposure in the general population. These data provide a baseline for future studies on respiratory mucosal immune responses and for the development of mucosal immune-based diagnostics.


Asunto(s)
Biomarcadores , Mucosa Respiratoria , Estaciones del Año , Humanos , Adulto , Adolescente , Anciano , Masculino , Femenino , Niño , Persona de Mediana Edad , Preescolar , Lactante , Anciano de 80 o más Años , Mucosa Respiratoria/inmunología , Factores de Edad , Adulto Joven , Recién Nacido , Inmunidad Mucosa
2.
Indoor Air ; 28(6): 950-962, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-29989219

RESUMEN

Indoor go-kart driving and viewing is enjoyed by people of all ages. However, it may pose health hazards, especially for children, pregnant women, cardiovascular patients, and elderly individuals. Depending on the race length, for example, high concentrations of various contaminants may result in severe health problems. Therefore, this project investigated the Indoor Air Quality of eight indoor go-kart facilities. In general, karts that used regular fuel produced the highest concentrations of CO, benzene, TVOC, and BaP, with maximum levels up to 150 mg/m3 , 170 µg/m3 , 2690 µg/m3 , and 8.7 ng/m3 , respectively. As expected, the maximum CO concentrations at go-kart facilities that used liquid gas and electric karts (20 and <6 mg/m3 , respectively) were significantly lower than those at other facilities. The highest 95th percentile values for NO (2680 µg/m3 ) and NO2 (280 µg/m3 ) were measured for karts with liquid gas. The alkane, alkene, and cycloalkane groups, as well as benzene and the alkyl benzenes, were the predominant components of the measured TVOCs. Overall, owners of indoor go-kart tracks should ensure that the ventilation with regard to combustion products is optimally adapted in any case to reduce the levels of critical air pollutants.


Asunto(s)
Contaminantes Atmosféricos/análisis , Monóxido de Carbono/análisis , Instalaciones Públicas , Recreación , Emisiones de Vehículos , Monitoreo del Ambiente/métodos , Alemania
3.
Neurocase ; 21(6): 674-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25360766

RESUMEN

Poststroke central pain (PSCP) can be a debilitating medication-refractory disorder. We report a single case where right unilateral ventral capsule/ventral striatum (VC/VS) deep brain stimulation was used to treat PSCP and inadvertently induced a smile without euphoria. The patient was a 69 year-old woman who had a stroke with resultant dysesthesia and allodynia in her left hemibody and also a painful left hemibody dystonia. In her case, VC/VS stimulation induced a smile phenomenon, but without a euphoric sensation. This phenomenon was different from the typical smile responses we have observed in obsessive-compulsive disorder cases. This difference was considered to be possibly attributable to impairment in the emotional smile pathway.


Asunto(s)
Estimulación Encefálica Profunda , Euforia/fisiología , Cápsula Interna/fisiopatología , Sonrisa/fisiología , Estriado Ventral/fisiopatología , Anciano , Femenino , Humanos , Cápsula Interna/cirugía , Dolor/etiología , Dolor/fisiopatología , Manejo del Dolor , Accidente Cerebrovascular/complicaciones , Estriado Ventral/cirugía
4.
Sci Rep ; 12(1): 5935, 2022 04 08.
Artículo en Inglés | MEDLINE | ID: mdl-35396570

RESUMEN

mRNA- and vector-based vaccines are used at a large scale to prevent COVID-19. We compared Spike S1-specific (S1) IgG antibodies after vaccination with mRNA-based (Comirnaty, Spikevax) or vector-based (Janssen, Vaxzevria) vaccines, using samples from a Dutch nationwide cohort. In adults 18-64 years old (n = 2412), the median vaccination interval between the two doses was 77 days for Vaxzevria (interquartile range, IQR: 69-77), 35 days (28-35) for Comirnaty and 33 days (28-35) for Spikevax. mRNA vaccines induced faster inclines and higher S1 antibodies compared to vector-based vaccines. For all vaccines, one dose resulted in boosting of S1 antibodies in adults with a history of SARS-CoV-2 infection. For Comirnaty, two to four months following the second dose (n = 196), S1 antibodies in adults aged 18-64 years old (436 BAU/mL, IQR: 328-891) were less variable and median concentrations higher compared to those in persons ≥ 80 years old (366, 177-743), but differences were not statistically significant (p > 0.100). Nearly all participants seroconverted following COVID-19 vaccination, including the aging population. These data confirm results from controlled vaccine trials in a general population, including vulnerable groups.


Asunto(s)
COVID-19 , SARS-CoV-2 , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales , COVID-19/prevención & control , Vacunas contra la COVID-19 , Humanos , Inmunoglobulina G , Cinética , Persona de Mediana Edad , ARN Mensajero , SARS-CoV-2/genética , Vacunación , Adulto Joven
5.
Sci Transl Med ; 9(416)2017 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-29141888

RESUMEN

Dyspnea is a frequent, devastating, and poorly understood symptom of advanced lung cancer. In our cohort, among 519 patients who underwent a computed tomography scan for the diagnosis of lung cancer, 250 had a mean pulmonary artery diameter of >28 mm, indicating pulmonary hypertension (PH). In human lung cancer tissue, we consistently observed increased vascular remodeling and perivascular inflammatory cell accumulation (macrophages/lymphocytes). Vascular remodeling, PH, and perivascular inflammatory cell accumulation were mimicked in three mouse models of lung cancer (LLC1, KRasLA2 , and cRaf-BxB). In contrast, NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ immunodeficient xenograft and dominant-negative IKK2 mutant triple transgenic (Sftpc-rtTA/Tet-O-Ikk2DN) mice did not develop PH. Coculturing human lung cancer cells with macrophages and lymphocytes strongly up-regulated cytokine release, provoking enhanced migration, apoptosis resistance, and phosphodiesterase 5 (PDE5)-mediated up-regulation of human lung vascular cells, which are typical features of PH. The PDE5 inhibitor sildenafil largely suppressed PH in the LLC1 model. We conclude that lung cancer-associated PH represents a distinct PH category; targeting inflammation in the microenvironment and PDE5 offers a potential therapeutic option.


Asunto(s)
Disnea/fisiopatología , Hipertensión Pulmonar/inmunología , Hipertensión Pulmonar/fisiopatología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/fisiopatología , Animales , Apoptosis/fisiología , Línea Celular Tumoral , Células Cultivadas , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/metabolismo , Células Dendríticas , Disnea/inmunología , Ecocardiografía , Humanos , Hipertensión Pulmonar/etiología , Inmunohistoquímica , Técnicas In Vitro , Inflamación/inmunología , Inflamación/fisiopatología , Neoplasias Pulmonares/complicaciones , Macrófagos/metabolismo , Ratones , Ratones Endogámicos C57BL , FN-kappa B/metabolismo , Linfocitos T/metabolismo
6.
Mov Disord Clin Pract ; 3(2): 139-145, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-30713906

RESUMEN

BACKGROUND: DBS has proven to be an effective therapy for Parkinson's disease, essential tremor, and primary dystonia. Mixed results have been reported in case series for other hyperkinetic disorders, and sparse data are available regarding secondary movement disorders. We report on the clinical effects of bilateral globus pallidus internus (GPi) DBS, a progressive mitochondrial cytopathy. METHODS: A single patient with myoclonus and dystonia syndrome secondary to a mitochondrial cytopathy with history of perinatal hypoxia was identified from our University of Florida DBS database. Demographics, clinical, surgical, and DBS data were documented. RESULTS: At 6 months post-DBS, we observed a 32% (361 to 527) improvement on quality of life (36-item Medical Outcome Study Short-Form Health Survey; SF-36). Objective clinical scales revealed a 33% (143 to 96) improvement in the Unified Myoclonus Rating Scale (UMRS) total score. The UMRS action myoclonus subsection revealed a 29% (69 to 46) improvement. No significant changes were observed in the Burke-Fahn-Mardsen Dystonia Rating Scale (BFMDRS). After 1-year follow-up, a worsening of 59% (527 to 215) was observed in the SF-36 scale, of 19% (28.5 to 35) in the BFMDRS, and of 23% (96 to 124) in the UMRS. However, the frequency and intensity of action myoclonus scores remained lower when compared to baseline scores. CONCLUSIONS: Although we observed a loss of benefit in the long term for most quality-of-life and clinical outcomes, the DBS effects on action myoclonus seemed to remain stable. Longer follow-up studies are necessary to confirm our short-term and unblinded findings.

9.
Appl Neuropsychol ; 9(2): 110-3, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12214821

RESUMEN

This study provides normative data about the cognitive functioning of 134 nonpsychiatric, non-neurological healthy elderly persons ranging from 60 to 85 years of age with the Neurobehavioral Cognitive Status Examination (Cognistat). Most areas of cognitive functioning remain grossly intact for all age levels. Construction and memory showed evidence of decline with age. These findings were compared with previous normative research with the Cognistat.


Asunto(s)
Envejecimiento/psicología , Cognición , Escala del Estado Mental , Pruebas Neuropsicológicas , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Escala del Estado Mental/estadística & datos numéricos , Persona de Mediana Edad , Valores de Referencia , Análisis y Desempeño de Tareas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA